Arycs Technologies | $24,000,000 | (Mar 13, 2026)
Ezra(2) | $8,000,000 | (Mar 13, 2026)
Freestyle | $10,000,000 | (Mar 13, 2026)
Certified by Founder
Lodge
Wugen
start up
United States
- St Louis, Missouri
- 17/03/2022
- Unknown
- $200,000,000
Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies.
Our lead program, WU-NK-101 is being tested in Phase 1b clinical trials. As the first product derived from our memory NK cell therapy platform, WU-NK-101 has shown robust efficacy (and safety) in AML patients.
- Industry Biotechnology
- Website https://www.wugen.com/
- LinkedIn https://www.linkedin.com/company/wugen/
Related People
Dan KempFounder
United States -
New York City Metropolitan Area
Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).
Mantis Space | $10,000,000 | (Mar 13, 2026)
Monteris Medical | $28,000,000 | (Mar 13, 2026)
Gumloop | $50,000,000 | (Mar 13, 2026)
Combat Medical Ltd | $3,472,639 | (Mar 13, 2026)
Qurrent | $15,000,000 | (Mar 13, 2026)
Waiv, formerly Owkin Dx | $33,000,000 | (Mar 13, 2026)
Carefam | $14,500,000 | (Mar 13, 2026)
Option Circle | $3,000,000 | (Mar 12, 2026)
AgentMail (YC S25) | $6,000,000 | (Mar 12, 2026)